Peptidomimetic nitriles as selective inhibitors for the malarial cysteine protease falcipain-2

Proteases of protozoan parasites have emerged as promising targets in drug design and discovery due to their indispensable roles in the life cycles of the parasites. For the development of new therapeutic agents against the malarial parasite Plasmodium falciparum, attention has turned to a family of cysteine proteases taking part in the degradation of human haemoglobin. The falcipains have key functions in this metabolic process, making them attractive targets for the development of novel antimalarials. To inhibit the cathepsin L-like cysteine protease falcipain-2, we designed peptidomimetic nitriles through rational structure-based molecular modelling focusing on the optimal occupancy of the selectivity-determining subpockets. A series of compounds was efficiently prepared and their biological activity assessed to explore the binding site properties of the target enzyme. Inhibitory affinities down to the single-digit micromolar range were obtained for this first generation of covalent, reversible cysteine protease inhibitors. High selectivity against human cathepsin B and L, as well as against the serine protease α-chymotrypsin was observed for the majority of the synthesised ligands. The ideal occupation of the selectivity-determining S2 pocket and the balanced electrophilicity of the nitrile group seem to be crucial to achieve both potency and selectivity.

[1]  K. Matthews Controlling and Coordinating Development in Vector-Transmitted Parasites , 2011, Science.

[2]  David A Winkler,et al.  Tripeptide motifs in biology: targets for peptidomimetic design. , 2011, Journal of medicinal chemistry.

[3]  F. Diederich,et al.  Potent and Selective Inhibition of Cysteine Proteases from Plasmodium falciparum and Trypanosoma brucei , 2010, ChemMedChem.

[4]  F. Fleming,et al.  Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore. , 2010, Journal of medicinal chemistry.

[5]  J. Gut,et al.  Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids. , 2010, Journal of medicinal chemistry.

[6]  Linda S. Brinen,et al.  Structures of Falcipain-2 and Falcipain-3 Bound to Small Molecule Inhibitors: Implications for Substrate Specificity‡ , 2009, Journal of medicinal chemistry.

[7]  F. Diederich,et al.  Structure-based drug design: exploring the proper filling of apolar pockets at enzyme active sites. , 2008, The Journal of organic chemistry.

[8]  M. Gütschow,et al.  Azadipeptide nitriles: highly potent and proteolytically stable inhibitors of papain-like cysteine proteases. , 2008, Angewandte Chemie.

[9]  F. Diederich,et al.  Exploring the Flap Pocket of the Antimalarial Target Plasmepsin II: The “55 % Rule” Applied to Enzymes , 2008, ChemMedChem.

[10]  J. Gut,et al.  Screening of Protease Inhibitors as Antiplasmodial Agents. Part I: Aziridines and Epoxides , 2007, ChemMedChem.

[11]  Jean-François Truchon,et al.  A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds. , 2007, Bioorganic & medicinal chemistry letters.

[12]  Xu Shen,et al.  Structural and Functional Characterization of Falcipain-2, a Hemoglobinase from the Malarial Parasite Plasmodium falciparum* , 2006, Journal of Biological Chemistry.

[13]  R. Fletterick,et al.  Structural basis for unique mechanisms of folding and hemoglobin binding by a malarial protease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Hay,et al.  The global distribution of clinical episodes of Plasmodium falciparum malaria , 2005, Nature.

[15]  D. Brömme,et al.  Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. , 2002, Chemical reviews.

[16]  D. Goldberg,et al.  Biological roles of proteases in parasitic protozoa. , 2002, Annual review of biochemistry.

[17]  D. Fairlie,et al.  Protease inhibitors: current status and future prospects. , 2000, Journal of medicinal chemistry.

[18]  P. Rosenthal,et al.  Proteases of protozoan parasites. , 1999, Advances in parasitology.

[19]  J. Rebek,et al.  The 55 % Solution: A Formula for Molecular Recognition in the Liquid State , 1998 .

[20]  T. Schirmeister,et al.  Cysteine Proteases and Their Inhibitors. , 1997, Chemical reviews.

[21]  Paul R. Gerber,et al.  MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry , 1995, J. Comput. Aided Mol. Des..

[22]  R. S. Coleman,et al.  Reversible covalent inhibition of papain by a peptide nitrile. Carbon-13 NMR evidence for a thioimidate ester adduct , 1986 .